The following is a summary of “Reducing plastic waste in intensive care from longer use of intravenous administration and ...

Berenberg Bank analyst Victoria Lambert maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9 – Research Report) yesterday and set a ...

J.P. Morgan analyst David Adlington maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9 – Research Report) today and set a price ...

The U.S. Astronaut Hall of Fame will honor its 2025 class of inductees, record-setting space travelers Peggy Whitson and ...

By declaring he’d put tariffs on goods from the South American country, the president imperiled a growing influx of foreign ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...

Some hospital-at-home alternative are entirely virtual, while others don't require patients to visit a hospital first.

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Cybin (NYSE:CYBN – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a ...